MPR3d
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Managed Healthcare Executive7d
FDA Approves Amvuttra for ATTR-CM in Extended Label
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
Zacks Investment Research on MSN1d
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
Intellia Therapeutics NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation ...
Healio7d
FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
BridgeBio announces Japanese MHLW approved acoramidis for treating ATTR-CM
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
TCTMD7d
Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
pharmaphorum7d
Alnylam joins three-way contest in ATTR cardiomyopathy
Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...
Pharmaceutical Technology on MSN7d
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.
Medscape7d
FDA Expands Vutrisiran Indication to ATTR-Cardiomyopathy
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...
PMLive4d
Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.